Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01242397
Other study ID # MiRBi- Acosta
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received November 10, 2010
Last updated December 1, 2010
Start date January 2011
Est. completion date January 2013

Study information

Verified date November 2009
Source Trinity Medical Center, Illinois
Contact Helbert Acosta, MD
Phone 309-236-0810
Email mirbiacosta@gmail.com
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to show that CRT(Cardiac Resynchronization Therapy) pacing in patients with severe functional MR (Mitral Regurgitation) who are not currently indicated for CRT will demonstrate chronic benefit of MR reduction( via echo measured MR/LA area and ERO per American Society of ECHO guidelines) and to show that CRT pacing is safe in these patients.


Description:

Approximately 50 patients will be randomized, followed and analyzed in this prospective study. Patients who meet all inclusion and no exclusion criteria will be enrolled and implanted with a CRT system. Baseline evaluation, which includes clinical symptom evaluation and an echocardiogram, will be performed at the time of randomization, which should occur as soon after device implant as possible but no later than 2 week post -implant. The baseline echocardiogram should be acquired prior to the device being programmed to the randomized setting. Repeat echocardiograms and scheduled follow-up evaluations will be performed at the end of each 3 month crossover period.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date January 2013
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient is at least 18 years of age

- Patients with moderate-to-severe or severe functional MR.

- EROA > 40 mm2 and an MR/LA > 40% (severe)

- 30 = EROA = 40 mm2 and 30 = MR/LA = 40% (moderate-to-severe)

- Baseline rates of 50-90 beats per minute (patients with sinus rhythm) or AF

- QRS < 120 ms

- LVEF < 35%

- Willing to sign informed consent

- On standard stable heart failure medical regimen (beta blockers and ACE-I or ARBs) for at least 1 month before randomization, if tolerated

- Patient has the ability to understand the requirements of the study, including consent for use and disclosure of research-related information

- Patient has the ability to comply with study procedures and protocol, including required study visits

Exclusion Criteria:

- candidate for CRT or has a previously implanted CRT device

- previously implanted implantable pulse generators (IPG) or implantable cardioverter defibrillator (ICD) with at least 10 % pacing in the right ventricle

- patient has life expectancy <6 months

- patient is pregnant

- significant aortic stenosis

- uncontrolled hypertension

- mitral valve stenosis

- severe mitral valve calcification

- ruptured chordae tendinae or papillary muscle

- mitral valve leaflet disorders (i.e. endocarditis, lupus, tumors, rheumatic heart disease)

- chronic mitral leaflet degeneration (ie. Marfans)

- previous valve replacement or surgery

- IV inotropes or IV vasodilators

- candidate for mitral valve repair or replacement surgery within the next 6 months

- patient has in-hospital acute coronary syndrome (ACS) (NSTEMI/STEMI) prior to randomization

- patient has planned or elective percutaneous coronary intervention (PCI) or other non-cardiac surgery prior to randomization

- patient is currently enrolled in an investigational drug or device study

- patient is clinically unstable per PI assessment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
CRT pacing
The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.

Locations

Country Name City State
n/a

Sponsors (5)

Lead Sponsor Collaborator
Trinity Medical Center, Illinois Duke University, Georgia Regents University, Massachusetts General Hospital, Medtronic

Outcome

Type Measure Description Time frame Safety issue
Primary Chronic(8 months post-implant) benefit of MR reduction To show that CRT pacing in patients with severe functional MR who are not currently indicated for CRT will demonstrate chronic(8 months post-implant) benefit of MR reduction (via echo measured MR/LA area and ERO per American Society of Echo guidelines) Chronic Yes
Secondary To compare MR Severity (ERO and MR/LA area), heart volume and dimensions via echo and clinical symptoms between two pacing modalities Secondary objectives will compare MR severity (ERO and MR/LA area), heart volume and dimensions via echo (LA and LV), LVEF via echo (Simpson's method and clinical sypmtoms (NYHA class, QOL, 6MHW distance) between the two pacing modalities (CRT ON and OFF) Chronic No
See also
  Status Clinical Trial Phase
Completed NCT03278574 - Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease N/A
Suspended NCT04960280 - A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease N/A
Recruiting NCT05021614 - Valveclip® Transcatheter Mitral Valve Repair Study N/A
Not yet recruiting NCT06465745 - AltaValve Pivotal Trial N/A
Not yet recruiting NCT06167213 - ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral N/A
Withdrawn NCT05040451 - Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
Withdrawn NCT03714412 - Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System N/A
Recruiting NCT02592889 - (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Phase 4
Completed NCT02355418 - The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
Not yet recruiting NCT01431222 - Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Phase 4
Completed NCT01841554 - Cardioband With Transfemoral Delivery System N/A
Not yet recruiting NCT03870516 - Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery N/A
Active, not recruiting NCT03230747 - SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation N/A
Enrolling by invitation NCT04031274 - Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
Completed NCT05836480 - Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
Completed NCT05836532 - Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
Completed NCT05850026 - Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Recruiting NCT03975998 - Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
Completed NCT01162083 - Identifying an Ideal Cardiopulmonary Exercise Test Parameter N/A
Suspended NCT00787293 - Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients Phase 2